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Abstract
In severe asthma, bronchodilator- and steroid-insensitive airflow obstruction develops through unknown mechanisms
characterized by increased lung airway smooth muscle (ASM) mass and stiffness. We explored the role of a Regulator of G-
protein Signaling protein (RGS4) in the ASM hyperplasia and reduced contractile capacity characteristic of advanced asthma.
Using immunocytochemical staining, ASM expression of RGS4 was determined in endobronchial biopsies from healthy
subjects and those from subjects with mild, moderate and severe asthma. Cell proliferation assays, agonist-induced calcium
mobilization and bronchoconstriction were determined in cultured human ASM cells and in human precision cut lung slices.
Using gain- and loss-of-function approaches, the precise role of RGS proteins was determined in stimulating human ASM
proliferation and inhibiting bronchoconstriction. RGS4 expression was restricted to a subpopulation of ASM and was
specifically upregulated by mitogens, which induced a hyperproliferative and hypocontractile ASM phenotype similar to
that observed in recalcitrant asthma. RGS4 expression was markedly increased in bronchial smooth muscle of patients with
severe asthma, and expression correlated significantly with reduced pulmonary function. Whereas RGS4 inhibited G protein-
coupled receptor (GPCR)-mediated bronchoconstriction, unexpectedly RGS4 was required for PDGF-induced proliferation
and sustained activation of PI3K, a mitogenic signaling molecule that regulates ASM proliferation. These studies indicate
that increased RGS4 expression promotes a phenotypic switch of ASM, evoking irreversible airway obstruction in subjects
with severe asthma.
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Introduction
Asthma, a common respiratory disease, manifests by airway
inflammation, hyperresponsiveness and reversible luminal ob-
struction. Despite research efforts, 15%–25% of patients with
asthma develop irreversible airway obstruction, which is refractory
to steroids and bronchodilators, and disproportionately account
for asthma morbidity and mortality [1,2]. In biopsies of the
bronchial wall, increases in the mass of airway smooth muscle
(ASM), the pivotal cell regulating bronchomotor tone, in part
defines airway remodeling in severe asthma [2]. However, the
contribution of increases in smooth muscle mass to irreversible
airway obstruction remains controversial.
Phenotypic plasticity defines the ability of smooth muscle to
switch between a contractile and synthetic state [3,4]. Although
characteristic of smooth muscle in cell culture, phenotypic
plasticity of smooth muscle in disease states remains controversial
[3,4]. Proliferative smooth muscle manifests abundant organelles
for protein and lipid synthesis, increased mitochondria and
diminished expression of contractile apparatus and associated
proteins [5,6,7]. Whether all or select populations of smooth
muscle in vivo retain a proliferative capacity and whether distinct
signaling pathways serve as master switches to promote smooth
muscle growth and inhibit agonist-induced contraction remain
unknown.
Regulators of G protein signaling (RGS) proteins inhibit GPCR
function by binding activated (GTP-bound) Ga subunits and
accelerating GTP hydrolysis by Ga [8]. This GTPase accelerating
(GAP) activity hastens the return of Ga to an inactive (GDP-
bound) form, promoting rapid termination of G protein signaling.
Unrelated to their GAP function, RGS proteins of the R4
subfamily, which includes RGS1–5, 8, 10, 13, 18 and 21, regulate
activity of PI3K by interacting with its regulatory p85a subunit
[9]. The associated PI3K subunit p110 catalyzes the formation of
phosphatidylinositol phosphate (PIP)3 from membrane PIP2,
activating signaling molecules involved in cell growth and
synthetic function, such as Akt [10]. p85, an adaptor, co-localizes
p110 with receptors and signaling complexes at the plasma
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e28504membrane [11]. RGS13 inhibited rapid antigen-IgE-induced
degranulation of mast cells by limiting association of PI3K with
the IgE receptor (FceRI) [9]. In breast cancer cells, RGS16
reduced epidermal growth factor (EGF)-evoked proliferation by
inhibiting PI3K signalosome formation [12].
Given the dual function of RGS proteins in GPCR and PI3K
signaling and the importance of these pathways for ASM
contraction and proliferation, respectively, we investigated their
expression and function in human ASM (HASM) cells in severe
asthma.
Materials and Methods
TNFa and IL-1b were obtained from Sigma. PDGF, EGF,
thrombin and histamine were sourced from Calbiochem. Signal-
ing inhibitors for PI3K (LY-294002), MEK/ERK (U0126),
p38MAPK (SB-203580) and JAK (DBI) were obtained from
Calbiochem. RNA extraction and DNAse digestion were per-
formed using RNEasy Kit and RNAse free DNAse from Qiagen.
Primers and reagents for RT-PCR were obtained commercially
from Applied Biosystems. Ingredients for cell lyse buffers, protease
inhibitor cocktails, protein quantification reagents and allied
western blotting resources were obtained from BD Biosciences.
All cell culture reagents including media and supplements were
obtained from nitrogen.
ASM culture and lentiviral transduction
All in vitro studies used HASM isolated from surgically excised
tracheal segments of lung tissue donors (NDRI) and cultured in
Ham’s F-12 medium supplemented with 10% FBS, 100 units/ml
penicillin, 0.1 mg/ml streptomycin and 2.5 mg/ml amphotericin
B. All experiments were performed using cultures within 2
nd to 4
th
passages, after staining for native contractile proteins using
monoclonal antibodies (mAb) against a-smooth muscle actin and
myosin (Santa Cruz Biotechnology). Cell purity was consistently
over 95%. For development of ShRGS4 and ShCnt cells, ASM cells
were transduced by using Polybrene and lentiviral particles
encoding RGS4-specific or scrambled non-coding 19–25 nt
shRNA sequences (Santa Cruz Biotechnology). After transduction,
stable HASM cell lines expressing shRNA were isolated via
puromycin selection. After each passage, the efficiency of silencing
was confirmed by RT-PCR using gene-specific primers supplied
by the manufacturer.
Clinical subjects
Subjects with asthma and non-asthmatic controls were recruited
from Leicester, UK. Subjects with asthma had a consistent history
and objective evidence of asthma, as described previously [13].
Subjects underwent extensive clinical characterization including
video-assisted fiberoptic bronchoscopic examination. The study
was approved by the Leicestershire Ethics Committees. All
patients gave their written informed consent.
Histology and immunofluorescence studies
For staining of bronchial biopsies, sequential 2-mm sections were
sectioned from glycomethacrylate-embedded explants and stained
using mAb against a-smooth muscle actin (Dako, Ely, UK), and
polyclonal RGS4 (Santa Cruz Biotechnology, Heidelberg, Ger-
many) or appropriate isotype controls (Dako). RGS4
+ cells were
enumerated/mm
2 ASM in the ASM bundle or adjacent to the
ASM bundle (,30 mm). A minimum area of 0.1 mm
2 was
considered accessible as described previously [13]. For immuno-
fluorescence experiments to determine PDGF-induced RGS4
expression, near confluent ASM cells on sterile glass coverslips
were fixed in 3% paraformaldehyde (Sigma), blocked with 1%
BSA and stained with polyclonal RGS4 (N-16, 1:500), Ab or
isotype-matched Ab. Cells were then stained with Alexa Fluor
488-conjugated anti-goat Ab (1:1,000, Invitrogen) and counter-
stained with DAPI (49-6-diamidino-2-phenylindole, Sigma) to
identify nuclei.
Biochemical studies
Co-immunoprecipitation experiments were performed follow-
ing methodology described earlier [9,14]. Antibodies against
phosphorylated-p85, p85 were obtained from Santa Cruz
Biotechnology. For immunoprecipitation experiments, cleared cell
lysates were incubated overnight at 4uC with anti-RGS4 tagged
TrueBlot anti-goat Ig IP beads (ebiosciences). Protein transfer was
followed by overnight incubation with Ab against phosphorylated-
p85 (1:500) and p85 (1:500). After incubation with HRP-
conjugated secondary antibody, the signal was detected with
ECL reagent (Promega).
p-Akt dynamics and Akt kinase assay
Differential kinetics of PDGF-mediated Akt phosphorylation
(Ser-473) was assayed in total protein lysates (1 mg/ml) from
ShRGS4 and ShCnt using Akt phospho STAR ELISA Kit
(Millipore) following enclosed protocols. Akt-dependent phosphor-
ylation of GSK-3 in ShRGS4 and ShCnt cells was determined using
an Akt Activity Assay Kit (Abcam).
Cell counting experiments and cell cycle analysis
ShCnt and ShRGS4 ASM cells were seeded at equal densities
(96610
3 cells/well) in 6-well plates and cultured for 7 days. Cells
were then serum deprived (Ham’s F-12 supplemented with 0.1%
BSA) for an additional 2 days before treatment with 10 ng/ml
PDGF for an additional 72 hours. Cultures were dissociated with
0.5% trypsin-EDTA (Invitrogen) solution and counted in triplicate
using the Coulter Z1 cell counter (Beckman Coulter). To analyze
cell cycle profiles, ShCnt and ShRGS4 ASM cells treated with/
without PDGF were prepared for propidium iodide staining using
CycleTest Plus Kit (BD Biosciences). Thereafter, DNA contents of
the stained nuclei were analyzed on a FACS Canto flow cytometer
and interpreted using Verity ModFit LT 3.0 Software.
Precision cut lung slices (PCLS) and small airway
responses
The smallest lobe of human lungs from lung tissue donors
(NDRI) was inflated with 2% (wt/vol) low-melting-point agarose
(Sigma), cored (8 mm in diameter) and sliced (250 mm thickness)
using a Krumdieck tissue slicer (Alabama Research and Develop-
ment) as described earlier [15]. Changes in small airway lumen to
increasing log concentration of CCh (10
28 to 10
24 mol/L) in
vehicle or PDGF-pre-treated (50 ng/ml for 8 hours) slices were
recorded using a CCD camera (Nikon ECLIPSE Model
No. TE2000-U, magnification 640) connected to a live video
feed (Evolution QEi, Model No. 32-0074A-130, video recorder). A
log half-maximum effective concentration (EC50) and maximum
drug effect (Emax) value for each airway were derived from a
concentration-response curve.
Intracellular Ca
2+ responses
Fura-2-loaded ShCnt and ShRGS4 ASM cells cultured on
coverslips were mounted onto an open slide chamber, placed
onto an inverted microscope and excited at 340 and 380 nm
wavelength, and emissions were collected at $450 nm wavelength
using a CCD camera (Nikon/Photon Technology International).
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e28504Figure 1. Human airway smooth muscle (HASM) mitogens induce RGS4 expression. (A) HASM cells express RGS mRNAs. RGS expression
was determined by real-time PCR in HASM cells left untreated or treated with PDGF for 2 h. Data presented are mean 6 SEM of 3 separate
experiments performed in triplicate using Gadph as an internal control, relative to RGS2 in untreated cells, set as ‘1’. (B) Analysis of RGS4 expression in
HASM cells treated with mitogens such as EGF (1 ng/ml), PDGF (10 ng/ml), thrombin and cytokines by real-time PCR. Data (mean 6 SEM) of 5
independent experiments. (C) Kinetics of PDGF-mediated RGS4 mRNA expression as a function of time. Values (mean 6 SEM of 3 separate
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2+ and
ionomycin, the ratio of fluorescence intensities at 340 and 380 nm
wavelength was determined using IgorPro (WaveMetrics). The
net Ca
2+ responses to contractile agonists were calculated by
subtracting the basal from that of the peak ratio values.
Statistical analysis
Graph Pad Prizm software was used to determine statistical
significance evaluated by a paired Students t-test for two groups or
analysis of variance (ANOVA) for multiple groups. P values of
,0.05 were considered significant.
Results
Mitogens selectively induce expression of RGS proteins
Human ASM cells predominantly expressed RGS2–5
(Figure 1A). Because RGS transcription often dynamically
responds to environmental cues, we analyzed RGS expression in
HASM treated with growth factors or cytokines associated with
airways dysfunction in asthma by real-time PCR. Exposure of
HASM to PDGF more effectively induced RGS4 mRNA and
protein expression (Figure 1A). Increased RGS4 transcripts were
also detected in cells exposed to EGF, thrombin, interleukin-1b
(IL-1b) and tumor necrosis factor a (TNFa) compared to
untreated cells (Figure 1B). PDGF-induced RGS4 expression
was dose- and time-dependent, with maximum expression
occurring at 6 hours (Figure 1C), and required active transcrip-
tion as it was inhibited by actinomycin D (Figure S1A). PDGF-
elicited RGS4 transcription also required activity of PI3K and
ERK1/2 but not p38 mitogen-activated protein (MAP) or Janus
(JAK) kinases (Figure S1B). Immunofluorescent staining with an
RGS4-specific antibody demonstrated minimal RGS4 expression
in quiescent cells whereas PDGF induced RGS4 expression in
nearly all HASM cells (Figure 1D). Consistent with prior studies
of other cell types [16], RGS4 localized in the cytoplasm and at
the plasma membrane of HASM cells.
RGS4 expression in ASM increases with asthma disease
severity
The selective induction of RGS4 by HASM mitogens suggested
a potential function in the ASM hyperplasia and fixed airway
obstruction associated with severe asthma. To characterize RGS4
expression in bronchial ASM bundles, we evaluated endobron-
chial biopsies from patients with asthma and age-matched healthy
Table 1. Clinical and sputum characteristics of patients categorized according to GINA.
Normal Mild-ModerateAsthma(GINA1=11,2=3,3=2) SevereAsthma(GINA4=11,5=4)
Number 13 16 15
Age* 47 (4) 49 (4) 52 (3)
Male/Female 8/5 6/9 5/10
Never/current/ex-smokers 11/0/2 12/0/4 12/0/3
Pack years* 0.5 (0.4) 2.9 (1.5) 1.5 (0.9)
Atopy n (%) 7 (54) 11 (69) 10 (67)
PC20FEV1 (mg/ml){ .16 0.37 (0.14–0.97)** 1.1 (0.3–3.6)**
FEV1% predicted* 97 (4) 83 (6) 79 (7)**
Pre-BD FEV1/FVC %* 83 (2) 72 (2) 68 (4)
BD response (%)* X 12 (4) 9 (3)
Inhaled corticosteroids (BDP/day) 0 300 (139) 1645 (197)
Oral corticosteroids n (%) 0 0 4 (27)
LABA n (%) 0 (0) 2 (13) 15 (100)
Sputum Cell Counts
TCC* 1.2 (0.2) 2.4 (0.5) 4.7 (1.2)**
Eosinophils %{ 0.3 (0.8) 1.0 (5.7) 2.8 (48)
Neutrophils %* 47 (13) 51 (8) 58 (8)
Macrophages %* 51 (9) 38 (6) 25 (6)**
Lymphocytes %* 1.8 (0.8) 1.0 (0.2) 1.5 (0.7)
Epithelial cells %* 3 (2) 4 (1) 7 (3)
GINA: Global Initiative for Asthma; BD: bronchodilator; LABA: long-acting bronchodilator; FEV1: forced expiratory volume in one second; TCC: total cell counts; BDP:
beclomethasone dipropionate; PC20FEV1: provocative concentration of methacholine to induce a 20% decrease in FEV1;
*mean (SE);
{geometric mean (95% CI);
{median (IQR);
**P,0.05 compared to control.
doi:10.1371/journal.pone.0028504.t001
experiments performed in triplicate) are relative to those of untreated cells, set as ‘1’ (D) RGS4 expression in untreated (top) or PDGF-treated (bottom)
HASM cells immunostained with polyclonal anti-RGS4 followed by Alexa Fluor 488-conjugated anti-IgG and DAPI. Left: High power (6506)
visualization of immunostaining with an anti-RGS4 antibody shows plasmalemma staining of RGS4 protein after PDGF. These data are representative
of triplicate wells in 2 separate cell lines. Bars represent 50 microns.
doi:10.1371/journal.pone.0028504.g001
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groups according to criteria established by the Global Initiative for
Asthma (GINA, http://www.ginasthma.com): healthy, mild-mod-
erate asthma and severe asthma (Table 1). Smooth muscle
bundles in bronchi from those with asthma had markedly
increased numbers of RGS4
+ ASM cells compared to those with
mild-moderate asthma or healthy subjects (Figures 2A–C).
RGS4
+ cells were found at the periphery of the ASM bundle
although some cells within the bundles also stained positively for a-
smooth muscle actin and RGS4. Notably, the number of RGS4
+
cells correlated inversely with pulmonary function as assessed by
the forced expiratory volume in 1 second (FEV1)( Figure 2D).
RGS4 expression is required for mitogen-induced
myocyte proliferation
Since RGS4 expression increased in proportion to ASM mass in
asthma and correlated with the severity of disease, we next
addressed whether ASM proliferation requires RGS4 expression.
To test this directly, we extinguished RGS4 expression in cultured
HASM cells using siRNA and measured proliferation in the
presence and absence of PDGF. RGS4 amounts were reduced
6466% in cells expressing an RGS4-specific shRNA relative to
cells expressing a scrambled control shRNA (Figure 3A).
Unexpectedly, PDGF-evoked proliferation was profoundly re-
duced in RGS4-depleted cells compared to control in the presence
Figure 2. RGS4 is expressed in proportion to lung ASM mass and disease severity in asthma. (A) RGS4 cells within and adjacent to the
asthma ASM bundle. Representative photomicrographs of a bronchial biopsy from a subject with asthma (2006) stained with isotype control
antibody (far left) or anti-RGS4 (3 right panels) which include the epithelium, lamina propria and ASM bundle. Far right panel shows staining of a
biopsy from a separate patient (4006) stained with antibodies against a-smooth muscle actin and RGS4. Arrows show RGS4
+ cells within and
adjacent to the ASM bundle. (B–C) Dot-plot of the number of RGS4
+ cells/mm
2 ASM within the ASM bundle (B) or RGS4
+ cells/mm
2 ASM within and
adjacent to the ASM bundle (C) in subjects with asthma and healthy controls. Horizontal bars depict the median value (P,0.05, Kruskal-Wallis test for
all across-group comparisons; P value for Dunn’s post test given on figure). (D) Correlation of RGS4
+ cells/mm
2 ASM with % predicted FEV1 in all
subjects and those with asthma alone, respectively, with correlation coefficient and P value provided.
doi:10.1371/journal.pone.0028504.g002
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fold increase in the percentage of cells in G2 phase of the cell cycle
compared to control, indicating growth arrest (P,0.0005)
(Figure 3C). To exclude the possibility that reduced cell numbers
were due to apoptosis or necrosis, we measured caspase 3 activity
or LDH levels, respectively. While ceramide treatment induced
HASM apoptosis as evidenced by a 10-fold increase in caspase 3
activity, minimal caspase 3 activity was detected in control or
RGS4-deficient cells in the presence or absence of PDGF (Figure
S2A). Accordingly, assessment of LDH levels showed no
significant differences in cell viability across all study groups
(Figure S2B).
These results suggest that, in contrast to the inhibition of PI3K-
mediated proliferation of neoplastic cells by RGS16, mitogen-
induced cell cycle progression of primary HASM cells unexpect-
edly required RGS4. Among several critical signaling events, robust
and durable activation of PI3K and its downstream effector S6K1
is required for HASM mitogenesis [1,17]. We hypothesized that
RGS4 mediates PDGF-elicited HASM growth by interacting with
the phosphorylated p85a subunit of PI3K and modulating activity
of the PI3K signaling pathway. PDGF induced tyrosine phos-
phorylation in HASM cells (Figure 3D). Consistent with our
previous studies with mast cells [9], we observed equivalent p85a
phosphorylation in control and RGS4-depleted HASM cells. To
characterize RGS4-p85a interactions in HASM, we immunopre-
cipitated proteins from untreated or PDGF-treated cells. We
detected RGS4 specifically in immunoprecipitates of phospho-
p85a from PDGF-treated but not untreated cells (Figure 3E).
Similarly, immunoprecipitation of RGS4 from lysates of PDGF-
treated HASM cells also extracted p-p85a PI3K.
To determine the molecular consequence(s) of RGS4-phospho-
p85a binding for PI3K signaling in HASM cells, we analyzed Akt
phosphorylation quantitatively by enzyme-linked immunosorbent
assay (ELISA). Growth factors including PDGF elicit Akt
phosphorylation at Thr-308 and Ser-473 residues, resulting in
phosphorylation of proliferation-critical effectors such as GSK-3
and S6K1 [18]. PDGF induced rapid Akt phosphorylation in
HASM cells as early as 5 minutes after stimulation, which
persisted for up to 5 hours (Figure 3F). Although we detected
similar levels of phospho-Akt in control and RGS4-shRNA
expressing cells at early time points, Akt phosphorylation was
dramatically reduced in RGS4-depleted cells 1–5 hours following
PDGF treatment. Consistent with the importance of Akt
phosphorylation for its kinase activity, prolonged PDGF treatment
of HASM elicited Akt activation as assessed by substrate (GSK-3b
phosphorylation by Akt immunoprecipitated from PDGF-treated
cells) (Figure 3G). We observed substantially reduced Akt kinase
activity in cells expressing RGS4 shRNA compared to control.
Finally, to determine the requirement of RGS4 for PDGF-induced
PI3K- and Akt-dependent cell cycle progression, we evaluated
expression of the Akt target gene cyclin D1 by quantitative real-time
PCR [19,20,21]. As expected, RGS4 depletion decreased PDGF-
evoked cyclin D1 expression (Figure 3H). The requirement of
RGS4 for mitogen-induced cell growth was specific to the PI3K
pathway, as siRNA-mediated extinction of RGS4 had no effect on
PDGF-evoked ERK phosphorylation in HASM (Figure S3).
Collectively, these studies demonstrate that PDGF induction of
RGS4 expression has a critical function in mitogen-induced ASM
hyperplasia through regulation of the PI3K-Akt signaling axis.
Mitogen-induced expression of RGS4 attenuates ASM
excitation-contraction coupling
Since RGS4 expression is upregulated in failing human hearts
[22], and overexpression of RGS4 impairs cardiac myocyte
contractility and increases heart failure in a mouse model [23], we
next examined whether mitogens attenuate agonist-induced
contractile responses in an RGS4-dependent manner. GPCR
agonists including carbachol, thrombin and histamine induce
ASM contraction through a Gaq-dependent pathway that
increases intracellular Ca
2+ concentrations. We treated human
precision cut lung slices (PCLS) with PDGF and measured airway
contraction by supravital microscopy. PDGF dramatically upre-
gulated RGS4 expression in lung slices (Figure 4A). Com-
pared to untreated slices, PDGF reduced the potency (log EC50)
of carbachol, an agonist of the M3 muscarinic receptor, as
well as maximal carbachol-evoked bronchoconstriction (Emax)
(Figure 4A). PDGF also diminished histamine-induced contrac-
tion, suggesting that PDGF modulates contractile responses
downstream of receptor activation through RGS4 upregulation.
To test this directly, we treated cultured HASM cells with
PDGF and measured intracellular Ca
2+ flux in quiescent and
agonist-treated cells. Acetylcholine (M3 receptor agonist), hista-
mine or thrombin induced a rapid increase in intracellular Ca
2+
levels, and PDGF pre-treatment markedly blunted these responses
(Figure 4B). In approximately 15% of HASM cells, PDGF
rendered cells completely unresponsive to agonists. To determine
whether PDGF inhibition of bronchoconstriction required
RGS4, we compared agonist-induced Ca
2+ responses in control
and RGS4-depleted cells. Knockdown of RGS4 completely
reversed PDGF-induced inhibition of histamine-evoked Ca
2+ flux
(Figure 4C). In parallel, we also determined that PDGF had little
effect on isoproterenol-induced bronchodilation of carbachol-
stimulated bronchoconstriction as shown in Figure S4.
Figure 3. RGS4 is required for PI3K and Akt-dependent HASM proliferation. (A) Gel photographs of RT-PCR analysis of RGS4 and GAPDH
expression in untreated and PDGF-treated HASM cells infected with lentiviruses encoding either control (ShCnt) or RGS4-specific (ShRGS4) shRNAs. (B)
RGS4 depletion attenuates PDGF-mediated HASM proliferation. Untransfected ShRGS4 and ShCnt ASM cells were serum-starved for 24 h followed by
treatment with serum-free medium or medium containing PDGF for an additional 72 h. Total cell numbers were determined using a Beckman Cell
Coulter counter (mean 6 SEM of 6 separate experiments performed in 2 cell lines). (C) PDGF-induced cell cycle traversal after 24 h analyzed by FACS
analysis of propidium iodide-stained nuclei isolated from ShRGS4 and ShCnt HASM cells. (D) Analysis of p85a phosphorylation assessed by
immunoblotting of lysates of untreated or PDGF-treated ShCnt or ShRGS4 expressing HASM cells. Blots are representative of 3 separate experiments
performed in 2 cell lines. (E) Left: Immunoblot analysis of p-p85 PI3K, RGS4 and total p85 PI3K expression in untreated or PDGF-treated cells. Right:
Immunoblot analysis of lysates from untreated or PDGF-treated cells immunoprecipitated with indicated antibodies. Blots are representative of 3
separate experiments performed in 3 cell lines. (F) Kinetics of PDGF-mediated Akt phosphorylation were analyzed in lysates of ShRGS4 or ShCnt HASM
cells by ELISA. Data (mean 6 SEM) are expressed as fold change over basal, set as ‘1’ in 5 separate experiments. (G) Akt kinase activity in ShRGS4 or
ShCnt HASM cells in untreated or PDGF-treated cells. p-Akt (Ser-473) was immunoprecipitated from total cell lysates using a specific antibody
followed by incubation with recombinant GSK3. Phospho-GSK-3a/b (Ser-21/9) was quantified by colorimetric assay. Data (mean 6 SEM) are fold-
change over vehicle-treated ShCnt cells determined in 4 independent experiments measured in triplicate. (H) Total RNA was extracted from ShRGS4
and ShCnt HASM cells treated with PDGF or diluent for 8 h followed by analysis of relative cyclin D1 expression by real-time PCR. Data are mean 6
SEM of 6 independent experiments using 2 cell lines.
doi:10.1371/journal.pone.0028504.g003
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Severe asthma encompasses a variety of phenotypes that are
characterized by ages of onset [24], duration of disease, degree of
airflow impairment, presence of co-morbidity and types of
inflammation [25,26]. The majority of subjects with severe asthma
manifest a degree of irreversible airway obstruction despite
maximal bronchodilation and, in some, a lack of methacholine
responsiveness [25,27,28]. Severe asthma patients also experience
more frequent and sustained exacerbations as compared with that
of mild/moderate patients [24,25,26,27,28]. Given the irreversible
component of the disease, investigators have suggested in part that
airway remodeling and ASM hyperplasia may contribute to fixed
airway obstruction [24,26,27,28]. We now show that human ASM
proliferation requires expression of RGS4 protein, which interacts
with the p85 subunit of PI3K. RGS4 also inhibits agonist-induced
bronchoconstriction and calcium mobilization. Further, RGS4
expression in ASM cells is associated with increasing disease
severity and may serve as a unique biomarker and/or therapeutic
target to abrogate ASM hyperplasia and irreversible airway
obstruction in asthma.
The most well-known function of RGS proteins is to reduce
signaling output from GPCR activation. The importance of RGS
proteins in the dynamic control of signaling is supported by
Figure 4. PDGF markedly inhibits carbachol-induced bronchoconstriction in human small airways. (A) PCLS were obtained from healthy
donors and treated with medium or PDGF (50 ng/ml) for 8 h followed by analysis of carbachol-induced small airway constriction by microscopy. Log
EC50 and Emax values (mean 6 SEM) were determined in experiments on 16 airways obtained from 4 separate donors as described in Methods. (B)
PDGF attenuates agonist-induced increases in [Ca
2+]i. HASM cells were stimulated for 8 h with 10 ng/ml PDGF or diluent followed by measurement of
[Ca
2+]i using a Ca
2+-sensing fluorophore after stimulation with acetylcholine (ACh), histamine or thrombin. Single-cell calcium transients were
measured over a period of 300 sec. Table shows mean 6 SEM of peak [Ca
2+]i levels determined in 30 cells (P values determined by 2-tailed Student’s t
test). Bottom tracings represent [Ca
2+]i in individual cells (blue line=control, diluent-treated; red line=PDGF-treated). Middle tracings represent
group mean data 6 SEM shown in the shaded segments. (C) RGS4 is required for PDGF-mediated attenuation of agonist-induced [Ca
2+]i in HASM
cells. The mean responses are shown using thick curves, and the individual cell responses are shown using dashed curves.
doi:10.1371/journal.pone.0028504.g004
Figure 5. A schematic illustration of the role of RGS4 in modulating human ASM excitation-contraction coupling and mitogen-
induced proliferation. A model by which regulatory G protein signaling (RGS) molecules modulate agonist-induced contraction and growth factor-
induced mitogenesis. Growth factors stimulate receptor tyrosine kinases (RTK) coupled to small G proteins such as Ras and Src. Src then activates
phosphoinositide 3-kinase type IA (PI3K) and extracellular receptor kinase 1/2 (ERK1/2). Subsequently, PI3K activates protein kinase B (PKB) and
mammalian target of rapamycin (mTOR) that then stimulates S6 kinase (S6K1) phosphorylation. S6K1 phosphorylation induces expression of RGS and
other proteins necessary for cell cycle progression and proliferation. The expression of RGS colocalizes with PI3K and promotes prolonged PI3K
activation to facilitate cell cycle traversal. Agonists stimulate G protein-coupled receptors (GPCRs) through the activation of specific Ga subunits. PLCb
stimulation then generates IP3 that mediates calcium release through cytoplasmic calcium stores by binding to the IP3 and ryanodine receptors.
Increased calcium promotes actin-myosin cross bridge cycling in a myosin light chain (MLC) kinase-dependent manner. In parallel, G protein
activation stimulates Rho kinase activation that inhibits MLC phosphatase and also promotes regulatory MLC phosphorylation (calcium sensitivity).
Agonists and growth factors may activate ASM in a paracrine or autocrine manner. The activation of RTK pathways and the inhibition of agonist-
mediated force generation promote ASM hyperplasia that increases ASM mass and may contribute to irreversible airflow obstruction.
doi:10.1371/journal.pone.0028504.g005
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[14,29]. Different RGS proteins interact with varying preference
with members of the Gi/o and/or Gq families to reduce signaling.
In addition to the RGS domain, RGS proteins have a variety of
domains for non-GPCR protein-protein interactions, and thus
selectivity for activation of particular pathways may be obtained
by scaffolding mechanisms. Although few investigators have
explored whether RGS proteins modulate RTK signaling
pathways [30,31,32,33], our data suggest that RGS4 is essential
to regulate RTK-mediated ASM growth. RGS expression is highly
tissue- and cell-specific and, as such, imparts unique control of
cellular function [29,34].
However, although the RGS family includes GPCR kinases
(GRKs) such as b-adrenergic receptor kinase, about which much is
known, the function of the smallest RGS molecules, namely, the
B/R4 subfamily (RGS1–5, 8, 13, 16, 18, 21), remains unclear. In
HASM, we show that the B/R4 RGS3, 4 and 5 proteins are the
dominant RGS molecules expressed. Since RGS proteins can
profoundly modulate GPCR signaling downstream from the
receptor, conceptually B/R4 RGS proteins may modulate
agonist-induced ASM contractility at multiple levels. In aortic
smooth muscle, knockdown of RGS3 increased muscarinic 3
receptor (M3R)-dependent ERK activation but had no effect on
angiotensin II-evoked signaling, suggesting receptor selectivity
[35,36].
Given the necessity of RGS4 in regulating ASM proliferation,
we posited that patients with severe asthma, who manifested
marked increases in bronchial smooth muscle mass and irrevers-
ible airway obstruction, would manifest increased numbers of
RGS4
+ ASM cells. The numbers of RGS4
+ ASM cells correlated
with increasing disease severity. Interestingly, the RGS4
+ myo-
cytes localized in discrete areas of the bronchial smooth muscle
bundle suggesting heterogeneity of expression among myocytes.
The recent development of bronchial thermoplasty, which delivers
a thermal injury to the bronchial wall, appears to decrease ASM
mass and improve clinical outcomes in severe asthma [37,38]. The
location of the RGS4
+ ASM cells and the requirement of RGS
expression in mediating ASM proliferation suggest a particular
susceptibility of these cells to such an injury. Since the ASM cells
fail to regenerate after the thermal injury, RGS4
+ cells may
represent a unique population of ASM akin to skeletal myoblasts
that serve to replenish differentiated muscle.
Although phenotypic plasticity of smooth muscle has been
recognized for decades, the precise signaling pathways that
inhibit contractile responses and that promote smooth muscle
growth remain unknown. In cultured vascular smooth muscle,
mostly RGS2 expression, but also 1, 3 and 4, are increased after
stimulation with angiotensin II, PDGF, IL-1b or TGFb [30,31].
RGS5 is expressed in rat and human aortic smooth muscle but
not coronary or venous myocytes [35]. In cardiac muscle, RGS4
plays a critical role in regulating the chronotropic actions of
acetylcholine. Lack of RGS4 enhances sensitivity to carbachol-
induced bradycardia and evokes arrhythmias [39]. Others
reported that increases in cardiac muscle expression of RGS4
decreases cardiac inotropy that promotes heart failure [22]. In
myometrial smooth muscle, RGS12 expression is markedly
increased at term while other RGS proteins are unchanged
[40,41]. We now show that RGS4 promotes mitogen-induced
ASM growth through regulation of PI3K activity yet inhibits
agonist-induced contractile function by decreasing calcium
mobilization stimulated by agonists. Importantly, PDGF had
little effect on b-agonist-induced bronchodilation. Increases in
RGS4 expression by growth factors, which enhance ASM
mitogenesis, may impart a susceptibility to ASM hyperplasia in
asthma. In our study, cultured ASM cells were derived from the
proximal airway while the contractile responses were measured in
the distal airway. To address whether the proximal and distal
ASM responded differentially to agonists, cytosolic calcium
mobilization to agonists was also studied in the cultured ASM
and demonstrated that PDGF modulated agonist-induced
calcium levels in the cultured ASM. Despite these studies, we
recognize that proximal and distal ASM in vivo may undergo
differential growth responses, and further experiments are needed
to definitively demonstrate whether growth factors modulate
RGS4 expression, contraction and proliferation in vivo.
Although asthma is considered a disease of reversible airway
obstruction and inflammation, patients with severe disease
experience irreversible airflow obstruction refractory to current
therapies. Given the strikingly increased morbidity seen in this
subset of patients compared to those with mild/moderate asthma,
the need for new therapeutic approaches remains dire. We have
identified growth factor-mediated upregulation of RGS4 in ASM
as a deleterious event in severe asthma. RGS4 was required for
ASM hyperplasia and rendered cells poorly contractile, consistent
with a maladaptive phenotypic switch as shown in Figure 5.
Although asthma is characterized by airway hyperresponsiveness,
the data herein suggest that in severe disease, ASM becomes less
responsive, which fixes the airway luminal diameter. Therapeutic
approaches that decrease RGS4 expression or antagonize RGS4
function may prevent ASM hyperplasia and irreversible airway
obstruction while promoting a more responsive smooth muscle
phenotype.
Supporting Information
Figure S1 Mitogens induce RGS4 expression that re-
quires PI3K and ERK activation. (A) Mitogens transcription-
ally induce RGS4 in ASM cells. Pre-treatment of ASM cells with
actinomycin (5 mM) for 1 h abrogated PDGF-, EGF- and
thrombin-mediated RGS4 enhancement. (B) Assessment of
signaling mechanisms mediating PDGF-induced RGS4 transcrip-
tion. Real-time PCR analysis of HASM cells pre-treated with
pharmacological inhibitors of PI3K (10 mM), ERK (10 mM), p38
MAPK (10 mM) or JAK (100 nM) for 1 h prior to treatment with
PDGF for an additional 6 h. Data are mean 6 SEM of 4 separate
experiments performed in triplicate.
(TIF)
Figure S2 Inhibition of ASM proliferation by silencing
RGS4 has little effect on ASM apoptosis. (A) Apoptosis as
assessed by caspase 3 activity in PDGF or diluent-treated
untransfected (Untfr) shCnt- or shRGS4-expressing HASM cells
after 72 h. As a positive control, ceramide (40 mM) was used as an
inducer of caspase-dependent apoptosis. (B) LDH levels as a
measure of cell viability in Untfr shCnt or shRGS4 HASM cells. As a
positive control, Triton X-100 (3%) was used as an inducer of cell
toxicity. Data are mean 6 SEM of 4 separate experiments
performed in triplicate. Values (mean 6 SEM of 3 separate
experiments performed in triplicate) are relative to those of
vehicle-treated Untfr cells, set as ‘1’.
(TIF)
Figure S3 RGS4 depletion has no effect on PDGF-
induced ERK phosphorylation. Total cell lysates from
PDGF- or diluent-treated shCnt- or shRGS4-expressing HASM
cells were immunoblotted by using p-ERK1/2. Total ERK1/2
expression was used as a control for protein loading. Blots are
representative of 3 separate experiments performed in 2 cell lines.
(TIF)
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induced bronchodilation. PCLS were treated for 8 h with
PDGF (50 ng/ml), then bronchoconstricted with carbachol, and
cumulative additions of isoproterenol then added. As shown,
PDGF had little effect on isoproterenol-induced bronchodilation.
These experiments were performed in 5 slices obtained from 3
donors, and the data represent mean 6 standard deviations.
(TIF)
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